Dec 19 (Reuters) - BioMarin Pharmaceutical (BMRN) said on Friday it would acquire Amicus Therapeutics (FOLD) for about $4.8 billion, expanding its presence in rare metabolic diseases.
The drugmaker will pay $14.50 per share for Amicus, a premium of 33.1% to the stock's last close. Shares of Amicus surged 30%, while BioMarin rose nearly 5% in premarket trading.
The deal strengthens BioMarin's portfolio with Amicus' approved genetic disorder treatments including Galafold, an oral drug for Fabry disease, which is caused by a faulty gene that leads to a buildup of fatty substances in cells.
Amicus also markets a combination therapy Pombiliti and Opfolda for Pompe disease, a genetic condition in which a complex sugar called glycogen builds up in the body's cells.
Amicus also has U.S. rights to DMX-200, a potential treatment of a type of kidney disease known as focal segmental glomerulosclerosis.
BioMarin intends to finance the deal through a combination of cash on hand and about $3.7 billion of non-convertible debt financing.
The company's total cash and investments at the end of September 30 were about $2 billion.
The acquisition, which is expected to close in the second quarter of 2026, will add revenue immediately after the transaction closes, BioMarin said.
The deal is also expected to add to adjusted profit in the first 12 months after close and be substantially accretive beginning in 2027, the company said.
(Reporting by Christy Santhosh and Sriparna Roy in Bengaluru; Editing by Leroy Leo and Maju Samuel)
LATEST POSTS
- 1
9 African migrants died in freezing temperatures near Morocco-Algeria border - 2A coup too far: Why Benin's rebel soldiers failed where others in the region succeeded
- 3Green Inflections: A Manual for Inside Plants
- 4A Gustav Klimt painting is now the most expensive piece of modern art sold at auction. The fascinating history behind the $236 million 'Portrait of Elisabeth Lederer.'
- 5Figure out How to Amplify the Resale Worth of Your Kona SUV
- Israel faces widespread condemnation as NGO ban comes into effect
- Step by step instructions to Protect Your Speculations with Cd Rates
- Our favorite Space.com stories of 2025
- Man who grabbed Ariana Grande at 'Wicked: For Good' premiere also rushed Katy Perry onstage this year. Who is he and why is he doing this?
- From Dread to Certainty: Individual Accounts of Strengthening
- The Red Sea strategy: What does Israel stand to gain from recognizing Somaliland?
- A definitive Handbook for Securities exchange Money management
- Going with Children: Tips for Tranquil Family Get-aways
- Vote in favor of your Favored sort of footwear
